IL32 and juvenile idiopathic arthritis: IL-32 promotes the production of a number of pro-inflammatory molecules, including tumour necrosis factor alpha (TNFα) and interleukin 621, 22, 23, cytokines that are targeted in biologic therapies for JIA24, and is therefore a biologically plausible candidate gene for JIA pathogenesis.